Kornimate/medical-research-clean huggingface dataset:
relevance of the urine bacterial culture performed before double j ablation for post-operative urinary tract infection prevention

Conditions: Urinary Infection

Summary: the value of cytobacteriological examination of urine (cbeu) before double j catheter removal has not been demonstrated. the aim of this study is to define the interest of this cbeu.

double j stents are ureteral catheters that allow urine to flow from the kidney without difficulty. these catheters protect the ureterovesical anastomosis of a renal transplant or reduce the postoperative oedema, for example after stone removal by ureteroscopy. these catheters are removed in an outpatient setting under local anaesthesia. post ablation infections of double j catheters have been poorly studied but their incidence varied according to the populations and the definition used (10 to 54% for colonization, 1 to 10% for symptomatic infection). the national and international guidelines advocate a routine urine bacterial culture (ubc) before double j catheter removal as the procedure is in contact with urine; but there is no evidence of its interest. in case of positivity of this culture, it is recommended to delay the intervention or, what is more often chosen, to treat with antibiotic to cover the procedure. investigators can thus ask 2 questions: is it rightful to withdraw a double j removal while the ubc is falsely negative and in case of a positive bacterial culture is there an increased risk of post-ablation infection?

Eligibility criteria:
inclusion criteria: * participant ≥ 18 years of age * scheduled to have a double j catheter ablation * participants covered by or entitled to social security * written informed consent obtained from the participant * ability for participant to comply with the requirements of the study exclusion criteria: * patients already receiving antibiotics other than urological reasons and transplanted patients * study interventions contraindications * pregnancy, breastfeeding * patient under tutorship or curators * deprivation of liberty
effect of social media support and financial incentives on prep adherence

Conditions: Pre-Exposure Prophylaxis

Summary: the purpose of this study is to determine if social media support and financial incentives improve adherence to truvada as prep in african american, latino and asian msm aged 18 to 24 living in the washington, dc area who are at high risk for hiv acquisition.


Eligibility criteria:
inclusion criteria: * male assigned at birth (regardless of current gender identity) * age 18-24 * black/african american, latino or asian * hiv negative * history of unprotected anal sex with a man in the last 6 months * living within the dc metropolitan statistical area and anticipate remaining within the dc area for the next 6 months * not enrolled in any other hiv prevention trial * interested in taking prep * not a current prep user and have not taken prep in the last 30 days * able to provide informed consent exclusion criteria: * female sex at birth * age younger than 18 or older than 24 * caucasian * hiv positive * actively taking prep or having taken prep within 30 days of enrollment * chronic hepatitis b infection * known renal insufficiency * on probation or parole * any other conditions that the principal investigator may consider a contraindication to enrolling in the study
pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack

Conditions: Transient Ischemic Attack; Stroke; Aspirin; Clopidogrel

Summary: pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.

pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.

Eligibility criteria:
inclusion criteria: * age 18 and older. * stroke or transient ischemic attack (tia) while taking aspirin within one week of consent. * women of child-bearing potential will be included only if there is a negative pregnancy test and they agree to birth control during the treatment period. exclusion criteria: * any medical indication for a specific antiplatelet agent (aspirin, clopidogrel, ticlopidine, aggrenox), or an indication for a combination of antiplatelet agents. * any medical indication for anticoagulation, except subcutaneous heparin for deep vein thrombosis prophylaxis. * allergy to aspirin or clopidogrel.

Keywords: transient ischemic attack stroke aspirin clopidogrel
imx-150 cream for diabetic neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: the purpose of this study is to compare the effectiveness of two different dose of imx-150 to that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the feet.


Eligibility criteria:
inclusion criteria: * must have sufficient command and understanding of the english language to complete diaries and questionnaires * if female, may not be pregnant or lactating * can be treated on an outpatient basis * has a clinical diagnosis of type-1 or type ii diabetes with: confirmed diagnosis of diabetic distal symmetrical sensorimotor polyneuropathy and bilateral pain in the feet for at least 3 months. * must have a hemoglobin a1c value of 11% or less that is stable under treatment * agrees to use the test creams as specified for the 4 week period * willing to not use any other medications, including investigational medications, to treat pain symptoms of diabetic neuropathy while in study. exclusion criteria: * currently using any nitrate medications * currently using viagra®, levitra®, cialis® or other phosphodiesterase 5 inhibitors medications for erectile dysfunction * currently treated for symptoms of diabetic neuropathy, including but not limited to lyrica®, cymbalta® and transcutaneous stimulation * not on a stable dose for at least 4 weeks prior to study screening of other vasodilators required for underlying conditions * know allergy to nitroglycerin, propylene glycol or common moisturizing creams * history of migraine, cluster or vascular headaches, chronic pain with greater pain intensity than the pain of diabetic neuropathy or other chronic pain condition within the region of the diabetic peripheral neuropathy * amputation of more than one toe per foot * neurological disorder or skin condition that may alter local sensation in the feet * history of unstable medical problem, clinically significant screening laboratory test or any current medical condition that would contraindicate the administration of the study mediation, interfere with the study evaluations, or interfere with the patient's ability to comply with the study * history of drug (including cannabinoid) or alcohol abuse within the past year * cognitive or language difficulties that would impair completion of the pain assessment tool * within the past 3 months, have had either a myocardial infarction, uncontrolled hypotension, or uncontrolled hypertension * participated in a study of any investigational drug within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to screening * major abdominal, thoracic or vascular surgery within 6 months of the first dose of study medication * open lesions in the area where the cream is to be applied * fertile patients who are unable or unwilling to comply with the contraceptive requirements during the study period

Keywords: foot pain diabetic neuropathy pain diabetic peripheral neuropathy foot pain
efficacy and safety of pro-148 versus systane®, in patients with mild to moderate dry eye

Conditions: Dry Eye

Summary: the purpose of this study is to evaluate efficacy and safety of the ophthalmic solution pro-148 in the ocular surface of patients with mild to moderate dry eye compared with ophthalmic solution systane®

dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. current treatment is heavily weighted toward supplementation, stimulation, or preservation of aqueous tears. artificial tears are one of the primary treatments for dry eye; it is mainly palliative and focuses on reducing the symptoms of discomfort to improve quality of life for a patient. a phase iii randomized double-blind clinical trial will be conducted to evaluate efficacy and safety of the ophthalmic solution pro-148 in the ocular surface of patients with mild to moderate dry eye compared with ophthalmic solution systane®. patients will be randomized to receive one of the treatments for 60 days. efficacy and safety measures will be performed at baseline and at 60 days after treatment

Eligibility criteria:
inclusion criteria: * mild to moderate dry eye patients based on the report of international dry eye workshop (dews) * osdi score between 12 and 45 * provided informed consent exclusion criteria: * patients with one blind eye * visual acuity of 20/100 or worst in any eye * patients with any active ocular disease that would interfere with study interpretation * patients in treatment with any medication that could interfere with the study, contraindication of any medication used in the protocol * patients with history of hypersensitivity or contraindication for any drug used in the study * contact lens users * pregnant patients, at risk of pregnancy or breastfeeding * patients without birth control treatment * patients who had participated in any clinical trial in the last 90 days * legal or mentally disabled patients who could not give informed consent * patients who do not provide informed consent
topical application of latanoprost in diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: randomized double-blinded two-year intervention study with topical application of latanoprost or placebo eye drops in patients with diabetic retinopathy.

the primary objective is to study if a sustained contraction of pathologically dilated retinal arterioles can be obtained. retinal arteriolar diameter and the diameter response to increased blood pressure is studied using the dynamic vessel analyzer (imedos, germany. the secondary objective is to study whether the intervention can halt the development of diabetic retinopathy, which is assessed by optical coherence tomography (oct) scanning and fundus photography.

Eligibility criteria:
inclusion criteria: * age 20-36 years old * diabetes mellitus with retinopathy exclusion criteria: * pregnancy * previous ocular disease other than diabetic retinopathy * general disease with possible influence on the eye

Keywords: latanoprost vasodilation diabetic retinopathy
mnemonic for the ottawa ankle rule

Conditions: Ankle Trauma; Education

Summary: the purpose of this study is to evaluate wether the use of a mnemonic strategy could improve the recall of the ottawa ankle and foot rules' guidelines among medical students and residents


Eligibility criteria:
inclusion criteria: * being a medical student in rotation in pediatrics at chu sainte-justine * being a resident in pediatric emergency rotation at chu sainte-justine exclusion criteria: * none

Keywords: clinical decision rule ottawa ankle rule ottawa foot rule ankle trauma education foot trauma
ondansetron for the treatment of methamphetamine dependence - 1

Conditions: Amphetamine-Related Disorders

Summary: the purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

this study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Eligibility criteria:
inclusion criteria: 18 years of age. treatment seeking for meth dependence. exclusion criteria: please contact site director for more details.

Keywords: amphetamine dependence
the effectiveness of two osteoporosis drugs on prosthetic bone mineral density (bmd) loss after total hip arthroplasty(tha)

Conditions: Bone Density; Arthroplasty, Replacement, Hip

Summary: the purpose of this study is to evaluate whether alendronate and alfacalcidol are effective on prosthetic or lumbar spine bmd after total hip arthroplasty.


Eligibility criteria:
inclusion criteria: * osteoarthritis of the hip * patients after total hip arthroplasty exclusion criteria: * diseases related to bone metabolism * patients taking drugs which affect bone metabolism

Keywords: bisphosphonate, vitamin d3 total hip arthroplasty
effect of pitavastatin on bone

Conditions: Osteoporosis, Osteopenia; Hypercholesterolemia; Menopausal Osteoporosis

Summary: this clinical trial investigates the effects of pitavastatin on bone health in postmenopausal women with osteopenia or osteoporosis and hypercholesterolemia. given the high prevalence of osteoporosis in aging populations and the associated risks, even with existing treatments, this study addresses a critical gap in medical research. statins, specifically hmg-coa reductase inhibitors, are suggested to benefit bone metabolism by promoting bone formation and reducing resorption. however, the specific impact of pitavastatin on bone metabolism lacks clinical evidence. the study's primary goal is to determine the effects of a 12-month pitavastatin regimen on bone metabolism markers in this population. this research could significantly contribute to developing more effective osteoporosis treatments for postmenopausal women, combining bone health and cholesterol management strategies.


Eligibility criteria:
inclusion criteria: * patients who are under the age of 75 and are postmenopausal. * individuals diagnosed with osteopenia or osteoporosis, exhibiting a t-score ranging from -3.0 to -1.5. * patients with hypercholesterolemia starting pitavastatin for the first time. * patients exhibiting baseline bone resorption markers, specifically c-telopeptide levels of 0.300 ng/ml or above, or ntx levels above 16.5 nmolbce/l. exclusion criteria: * patients who have used a statin medication for more than one month within the last 3 months. * patients who have used oral or injectable glucocorticoids for more than one week within the last 3 months. * patients currently using thiazolidinediones, a class of oral antidiabetic medications. * patients undergoing treatment for malignant tumors.
pascal: safety and complications, experience after 1301 consecutive cases

Conditions: Bruch Rupture; Choroidal Detachment

Summary: to report the safety and incidence of adverse effects, during and after a successful photocoagulation for different pathologies using a pattern scan laser (pascal) system and its modified settings


Eligibility criteria:
inclusion criteria: * patients treated with pascal system exclusion criteria: * uncompleted file. * loss of follow-up.

Keywords: panretinal photocoagulation bruch rupture choroidal detachment complication rates
effect of introducer length on the rate of radial artery occlusion during endovascular coronary procedures

Conditions: Coronary Artery Disease

Summary: this study evaluates estimate impact of introducers length during endovascular coronary procedures on rate of a radial artery occlusion. for half of participants will use short introducers, while for other will use long introducers during transradial coronary intervention.

the transradial approach for coronary angiography and interventions is increasingly utilized around the world. radial artery occlusion is the most common significant complication after transradial catheterization, with incidence varying between 1% and 10%. endothelial injury of the radial artery and decrease in blood flow after sheath and catheter insertion appear to contribute to thrombus formation and are predisposing factors for radial artery occlusion. procedural factors can predict and influence radial artery occlusion incidence. sheath size and its relation to radial artery diameter, as well as the utilization of specific pharmacological agents (such as anticoagulants and vasodilators) have been studied. but, impact of introducer sheath length on the rate of a radial artery occlusion has not been studied. the investigators suggest that, longer introducer sheath sizes can prevented the vascular damage and a pro-thrombotic environment.

Eligibility criteria:
inclusion criteria: * age over 18 years old * applicability of transradial approach exclusion criteria: * failure of the transradial approach
effects of upper airway muscle training on obstructive sleep apnea severity

Conditions: Sleep Apnea

Summary: the purpose of this study is to evaluate the effect of asate silent sleep training on obstructive sleep apnea (osa) severity in patients with mild to moderate osa. the asate silent sleep training is a muscle strengthening program that uses exercise equipment (a musical instrument that is based on the didgeridoo). the equipment is connected to an application, which provides instruction on how to perform the strengthening exercises, measures the sound produced by the musical instrument, which enables the app to provide feedback on whether the individual should blow less or more and also tracks adherence to the strengthening program.


Eligibility criteria:
inclusion criteria: * age 21 to 50 * diagnosed by a physician with mild to moderate osa, based upon interpretation of data recorded on a take home sleep study * body mass index \< 30 kg/m2 * mild to moderate osa, ahi of 5-30 exclusion criteria: 1. apnea hypopnea index on overnight sleep study \> 30 per hour 2. currently practices didgeridoo 3. consumes more than 2 alcoholic beverages per day 4. history of chronic lung disease (e.g., copd, asthma) 5. oral maxillofacial issue or craniofacial musculoskeletal conditions 6. any treatment for osa (current or past) 7. mobile device use frequency \< once per week 8. homelessness 9. no reliable transportation to assessment sessions 10. planned social/family/employment obligations that would limit participant from engaging in asate silent sleep training during the intervention period 11. significant upper extremity weakness/paralysis or pain limiting ability to hold the medical didgeridoo 12. uncorrected low vision or blindness 13. deafness 14. no internet connection/chrome browser/mobile devices with ios and android 15. no usb port in computer 16. pregnancy
efficacy and safety of pneumostem® for ivh in premature infants (phase 2a)

Conditions: Cell Transplantation

Summary: the objective of this study is to evaluate the efficacy and safety of a single intraventricular administration of pneumostem® for treatment of intraventricular hemorrhage (ivh) in high-risk premature infants by comparing pneumostem-treated group with a control group.


Eligibility criteria:
inclusion criteria: * ivh grade 3-4 * age : within postnatal day 28 * gestational age: 23-\<34 weeks exclusion criteria: * patient with severe congenital abnormalities * patient with antenatal brain hemorrhage * patient with asphyxia or hypoxic ischemic encepalophathy * patient with chromosome anomalies (i.e. edward syndrome, patau syndrome, down syndrome, etc) or severe congenital malformation (hydrocephalus, encephalocele, etc) * patient with a concurrent severe congenital infection (i.e. herpes, toxoplasmosis, rubella, syphilis, aids, etc) * patient withcrp \> 30 mg/dl; severe sepsis or shock * patient with a history of participating in other clinical studies * patient who is considered inappropriate to participate in the study by the investigator
symphony il-6 study in patients at risk of severe sepsis

Conditions: Severe Sepsis

Summary: symphony il-6 is a device that quantitates human il-6 by fluorescence enzyme immunoassay (feia) from whole-blood specimens. use of symphony il- 6 removes the need for plasma separation before testing. symphony il-6 comprises two components, the symphony fluorescence immunoanalyzer and the symphony il-6 cartridge. whole blood is added to the cartridge and then up to six cartridges can be inserted into the immunoanalyzer. after 20 minutes a readout and printout are given with a quantitative il-6 concentration. the used cartridges are fully enclosed and can be easily disposed of in general hospital bio-waste. given the nature of this device and its portability, there is potential for future deployment in a near patient setting. this study is to establish an interleukin-6 (il-6) cutoff value using the symphony il-6 test for patients at high risk of severe sepsis caused by a covid-19 and/or influenza infection.


Eligibility criteria:
inclusion criteria: * whole-blood specimen collected in edta anticoagulant tube * subject is 22+ years of age * a minimum volume of 0.3 ml blood will be collected for symphony il-6 testing * subjects who have concurrently received crp test results * subject is confirmed to be covid-19 positive by an eua or fda cleared sars-cov-2 positive rt-pcr test, and/or the subject is confirmed to be influenza-a or influenza-b positive by an fda cleared test. exclusion criteria: * subject is receiving an anti-il-6 treatment * hemolyzed specimens

Keywords: sirs ards covid-19 influenza a influenza type b respiratory failure
prognostic biomarkers for pulpotomy outcome

Conditions: Pulpitis - Irreversible

Summary: this study will recruit 180 molars diagnosed with irreversible pulpitis. full pulpotomy will be performed on 120 teeth, while rct (root canal treatment) will be conducted on another cohort of 60 teeth as the control for assessing long-term outcomes. additionally, 12 blood samples and pulp tissues from healthy teeth receiving elective rct will be collected as the controls. the first pulpal blood sample will be collected after caries removal and pulp exposure. subsequently, the entire coronal pulp tissue will be removed and collected for histological examination, image-based spatial and scrna-seq analyses. a second pulpal blood sample will be collected from the radicular pulp tissue. both blood samples will be used to profile the inflammation-related biomarkers through multiplex immunoassays. the remaining pulp tissue will be covered by biodentine and restored with resin-based composite. pulpotomy treatment outcomes will be evaluated clinically and radiographically at 6 and 12 months. the biomarkers identified in the pulpal blood and histology and the single-cell transcriptomes of the coronal pulp will be compared with the treatment "success" and "failure" groups upon one year. the outcome of rct will be compared with that of full pulpotomy at 24 months.


Eligibility criteria:
inclusion criteria: * permanent molars showing clinical and radiographic evidence of a deep carious lesion (extend to the three-quarters thickness of dentine radiographically) extending close to the pulp chamber * clinical diagnosis of irreversible pulpitis, including spontaneous pain, lingering pain with cold stimulation, no or mild tenderness to percussion, normal apical tissue or widening of the periodontal ligament space but with no signs of periapical periodontitis (i.e., pai score 1 or 2) * positive response to cold and electric pulp test. exclusion criteria: * tooth with no response to the cold and electric tests, presence of apical radiolucency (greater than periodontal widening), signs of canal calcification and resorption, history of trauma, unrestorable or nonfunctional teeth, and evidence of perio-endo lesion * intraoperative bleeding time is more than 10 minutes or less than 10 μl pulpal blood can be obtained * patients with a compromised immune status (such as hiv or organ transplant) or with any history of taking analgesics/antibiotics in the past one week.